Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$0.57 USD
+0.01 (2.04%)
Updated Sep 19, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Cue Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -50.73 | -53.01 | -44.16 | -44.78 | -36.70 |
Depreciation/Amortization & Depletion | 0.36 | 0.63 | 1.25 | 1.14 | 0.81 |
Net Change from Assets/Liabilities | -0.93 | 0.36 | -4.39 | 5.43 | -5.77 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.35 | 10.22 | 8.46 | 5.72 | 10.86 |
Net Cash From Operating Activities | -39.96 | -41.81 | -38.84 | -32.49 | -30.80 |
Property & Equipment | 0.00 | -0.16 | -0.89 | -0.60 | 0.08 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 25.00 | -24.45 | 10.00 | 5.05 | 3.37 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 25.00 | -24.61 | 9.11 | 4.46 | 3.45 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.47 | 22.70 | 19.98 | 58.89 | 50.88 |
Issuance (Repayment) of Debt | 0.00 | 10.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -2.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 13.39 | 20.96 | -0.75 | -0.27 | -0.09 |
Net Cash from Financing Activities | 11.86 | 53.66 | 19.23 | 58.61 | 50.79 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -3.10 | -12.76 | -10.50 | 30.58 | 23.44 |
Cash at Beginning of Period | 51.76 | 64.52 | 75.02 | 44.44 | 21.00 |
Cash at End of Period | 48.67 | 51.76 | 64.52 | 75.02 | 44.44 |
Diluted Net EPS | -1.11 | -1.49 | -1.41 | -1.56 | -1.66 |
Fiscal Year End for Cue Biopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -22.52 | -12.35 | -50.73 | -37.30 | -26.29 |
Depreciation/Amortization & Depletion | 0.22 | 0.11 | 0.36 | 0.24 | 0.11 |
Net Change from Assets/Liabilities | -2.75 | -0.27 | -0.93 | -0.29 | -0.53 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.28 | 2.73 | 11.35 | 8.35 | 5.51 |
Net Cash From Operating Activities | -19.77 | -9.78 | -39.96 | -29.00 | -21.20 |
Property & Equipment | -0.07 | -0.06 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 25.00 | 25.00 | 20.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.07 | -0.06 | 25.00 | 25.00 | 20.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | 0.47 | 0.47 | 0.47 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -2.00 | -1.00 | -2.00 | -1.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 3.35 | 3.35 | 13.39 | 7.61 | 2.02 |
Net Cash from Financing Activities | 1.35 | 2.35 | 11.86 | 7.08 | 2.49 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -18.49 | -7.49 | -3.10 | 3.08 | 1.29 |
Cash at Beginning of Period | 48.67 | 48.67 | 51.76 | 51.76 | 51.76 |
Cash at End of Period | 30.18 | 41.18 | 48.67 | 54.84 | 53.05 |
Diluted Net EPS | -0.20 | -0.25 | -0.29 | -0.24 | -0.29 |